Iridex Corp $IRIX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Electromedical & Electrotherapeutic Apparatus
- Headquarters
- Mountain View, CA
- Fiscal year end
- January 3
- Shares outstanding
- 17,564,912 [10-Q 2026-08-18]
What the company doesAI summary of filing
IRIDEX Corporation is a revenue-generating ophthalmic medical technology company that develops and commercializes laser systems and related delivery devices for treating glaucoma and retinal diseases. The company sells laser consoles, delivery devices, and single-use disposable probes to ophthalmologists, hospitals, and surgical centers, primarily in the United States and internationally through a direct sales force and independent distributors. IRIDEX generates recurring revenue through equipment sales and consumable products, along with repair and service contracts. In fiscal year 2025, the company reported total revenues of $52.7 million and a net loss of $4.4 million. [10-K 2026-04-02]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jul 2026 | $24.36M | −$1.79M | −$1.16M | $4.68M | [10-Q 2026-08-18] |
| FY ended Jan 2026 | $52.67M | −$4.44M | −$2.12M | $6.03M | [10-K 2026-04-02] |
| FY ended Dec 2024 | $48.67M | −$8.91M | −$7.29M | $2.39M | [10-K 2026-04-02] |
- Quarterly cash burn
- −$580.5K
- Cash runway Estimate
- ~24.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 16,636,380 | [10-Q 2024-11-12] |
| 2025-03-21 | 16,789,027 | [10-K 2025-03-27] |
| 2025-05-08 | 16,789,027 | [10-Q 2025-05-13] |
| 2025-08-07 | 16,992,253 | [10-Q 2025-08-12] |
| 2025-11-06 | 17,189,981 | [10-Q 2025-11-12] |
| 2026-03-27 | 17,307,401 | [10-K 2026-04-02] |
| 2026-05-11 | 17,406,518 | [10-Q 2026-05-19] |
| 2026-08-13 | 17,564,912 | [10-Q 2026-08-18] |
- Shelf registration
- S-3 filed 2024-09-05; declared effective 2024-09-24 [S-3 2024-09-05]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-02] |
| 2025-05-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-20] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Mercer Patrick | other | 23,917 | $0.63 | [4 2026-10-05] |
| 2026-09-16 | Dizon Romeo R | buy | 7,900 | $0.63 | [4 2026-09-16] |
| 2026-09-14 | Dizon Romeo R | buy | 2,354 | $0.65 | [4 2026-09-14] |
| 2026-09-10 | Dizon Romeo R | buy | 5,100 | $0.68 | [4 2026-09-10] |
| 2026-08-24 | Dizon Romeo R | buy | 1,300 | $0.75 | [4 2026-08-24] |
| 2026-08-24 | Dizon Romeo R | buy | 5,368 | $0.75 | [4 2026-08-24] |
| 2026-03-30 | Lin Shih-Yao David | buy | 7,371 | $0.99 | [4 2026-10-07] |
| 2026-03-24 | Lin Shih-Yao David | buy | 4,549 | $1.33 | [4 2026-10-07] |
| 2026-03-23 | Lin Shih-Yao David | buy | 17,526 | $1.33 | [4 2026-10-07] |
| 2026-03-17 | Lin Shih-Yao David | buy | 22,805 | $1.31 | [4 2026-10-07] |
| 2026-03-16 | Lin Shih-Yao David | buy | 1,682 | $1.30 | [4 2026-10-07] |
| 2026-03-12 | Lin Shih-Yao David | buy | 967 | $1.32 | [4 2026-10-07] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-02 | 8-K | Listing notice or transfer |
| 2026-08-18 | 10-Q | Quarterly report |
| 2026-08-18 | 8-K | Results of operations |
| 2026-07-16 | 8-K | Shareholder vote results; Regulation FD disclosure |
| 2026-07-13 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-18 | 8-K | Other events |
| 2026-05-19 | 10-Q | Quarterly report |
| 2026-05-19 | 8-K | Results of operations |
| 2026-04-24 | DEF 14A | Proxy statement |
| 2026-04-02 | 10-K | Annual report |
| 2026-03-26 | 8-K | Results of operations |
| 2026-03-13 | 8-K | Material agreement entered; New financial obligation |
Alerts for $IRIX
Email me when Iridex Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.